GSK wins $196m US BARDA contract for anthrax antitoxin raxibacumab

20 Sep 2013

• By Donna Young

The US government has ordered 60,000 doses of GlaxoSmithKline's anthrax antitoxin raxibacumab under a four-year contract worth $196m with the Biomedical Advanced Research and Development Authority (BARDA).

GSK wins $196m US BARDA contract for anthrax antitoxin raxibacumab

More from Anti-infective

More from Therapy Areas